Skip to the page

Data / Drug companies / Civica, Inc.

Civica, Inc.: 103 products in the FDA NDC directory, labeler code 72572

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Civica, Inc. (labeler code 72572) lists 103 products in the FDA National Drug Code Directory, covering 61 finished drugs by generic name. By type: 103 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 9, 2026.

The request: Watch Civica, Inc. (FDA labeler code 72572): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
72572
Products in commercial distribution
103
Packages
105
Finished drugs by generic name
61
Prescription products
103
Over the counter products
0
Controlled substance products
Schedule II 4, Schedule III 2, Schedule IV 5
Flagged as original packager
94 of 94 products that carry the flag
Started marketing in the last 12 months
12
Products with a marketing end date set
3
Earliest marketing start
June 16, 1975
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)8279.6%
New drug applications (NDA)1817.5%
Biologics (BLA)21.9%
Authorized generics (NDA)11%

Products by type

TypeProductsShare
Prescription drugs103100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection3937.9%
Injection, solution2827.2%
Injection, powder, for solution1918.4%
Injection, powder, lyophilized, for solution109.7%
Injection, emulsion32.9%
Injection, solution, concentrate32.9%
Solution11%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Diazepam72572-175InjectionGeneric drugs (ANDA)September 9, 2026
Cefazolin72572-054Injection, powder, for solutionNew drug applications (NDA)August 18, 2026
Bumetanide72572-211Injection, solutionGeneric drugs (ANDA)August 1, 2026
Bumetanide72572-210Injection, solutionGeneric drugs (ANDA)August 1, 2026
Furosemide72572-275InjectionNew drug applications (NDA)July 13, 2026
Sodium Bicarbonate72572-200SolutionGeneric drugs (ANDA)June 10, 2026
Ketorolac Tromethamine72572-357Injection, solutionGeneric drugs (ANDA)April 1, 2026
Ketorolac Tromethamine72572-356Injection, solutionGeneric drugs (ANDA)April 1, 2026
Methylprednisolone Sodium Succinate72572-098Injection, powder, for solutionGeneric drugs (ANDA)December 1, 2025
Methylprednisolone Sodium Succinate72572-097Injection, powder, for solutionGeneric drugs (ANDA)December 1, 2025
Daptomycin72572-158Injection, powder, lyophilized, for solutionNew drug applications (NDA)November 28, 2025
Vancomycin Hydrochloride72572-029Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)November 10, 2025
Enoxaparin Sodium72572-280InjectionGeneric drugs (ANDA)November 1, 2025
Insulin glargine72572-424Injection, solutionBiologics (BLA)October 30, 2025
Insulin glargine72572-422Injection, solutionBiologics (BLA)October 30, 2025
Vasopressin72572-860Injection, solutionNew drug applications (NDA)October 22, 2025
Vancomycin Hydrochloride72572-207Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)October 13, 2025
Vancomycin Hydrochloride72572-105Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)October 13, 2025
Piperacillin and tazobactam72572-418Injection, powder, for solutionGeneric drugs (ANDA)September 8, 2025
Piperacillin and tazobactam72572-414Injection, powder, for solutionGeneric drugs (ANDA)September 8, 2025
Meropenem72572-412InjectionGeneric drugs (ANDA)September 8, 2025
Meropenem72572-410InjectionGeneric drugs (ANDA)September 8, 2025
Ampicillin sodium and sulbactam sodium72572-136Injection, powder, for solutionGeneric drugs (ANDA)September 8, 2025
Ampicillin sodium72572-094Injection, powder, for solutionGeneric drugs (ANDA)September 8, 2025
Ampicillin sodium72572-093Injection, powder, for solutionGeneric drugs (ANDA)September 8, 2025

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.